Home » Stocks » ANIX

Anixa Biosciences, Inc. (ANIX)

Stock Price: $5.04 USD 0.09 (1.82%)
Updated Mar 3, 2021 3:59 PM EST - Market closed
Market Cap 129.08M
Revenue (ttm) n/a
Net Income (ttm) -10.02M
Shares Out 22.23M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $5.04
Previous Close $4.95
Change ($) 0.09
Change (%) 1.82%
Day's Open 4.93
Day's Range 4.75 - 5.13
Day's Volume 234,725
52-Week Range 1.33 - 5.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 months ago

Anixa Biosciences (ANIX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

PRNewsWire - 7 months ago

SAN JOSE, Calif., July 10, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today...

PRNewsWire - 7 months ago

SAN JOSE, Calif., July 6, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...

PRNewsWire - 8 months ago

SAN JOSE, Calif., July 2, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for February 11th

Other stocks mentioned: ACBI, AFG

About ANIX

Anixa Biosciences, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine progr... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jan 1, 1987
CEO
Amit Kumar
Employees
3
Stock Exchange
NASDAQ
Ticker Symbol
ANIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price forecast is 8.75, which is an increase of 73.61% from the latest price.

Price Target
$8.75
(73.61% upside)
Analyst Consensus: Strong Buy